Primary antiphospholipid syndrome in pediatrics: beyond thrombosis. Report of 32 cases and review of the evidence

Alfonso-Ragnar Torres-Jimenez1*, Virginia Ramírez-Nova1, Adriana Ivonne Cespedes-Cruz1, Berenice Sanchez-Jara2, Alejandra Velazquez-Cruz1, Vilma Carolina Bekker-Méndez3 and Francisco Xavier Guerra-Castillo3

Abstract

Objective: Describe the frequency of thrombotic and non-thrombotic clinical manifestations, laboratory, treatment and prognosis in patients with pediatric primary antiphospholipid syndrome.

Material and methods: A retrospective study was carried out in patients with a diagnosis of primary antiphospholipid antibody syndrome, under 16 years of age, under follow-up by the pediatric rheumatology service of the General Hospital, National Medical Center, La Raza, from January 2013 to December 2020. The antiphospholipid syndrome was defined when it met the laboratory criteria of the Sidney criteria and the presence of thrombosis or non-criteria manifestations of the disease (hematological, neurological, cutaneous, renal, cardiac or pulmonary). Demographic, clinical, laboratory, treatment, and prognosis data were collected.

Results: We report 32 patients, 21 female (65%) and 11 male (35%), mean age 11.75 years, evolution time 16 weeks. Thrombosis 9 patients (28%), 1 arterial and 8 venous. Non-thrombotic manifestations; Hematologic: thrombocytopenia 22 patients (69%), autoimmune hemolytic anemia 13 (40%), Fisher-Evans syndrome 6 (19%), lupus anticoagulant with hypoprothrombinemia syndrome 2 (6%). Dermatological: livedo reticularis 20 (62%), skin ulcers 2 (6%), Raynaud’s phenomenon 8 (25%). Neurological: epilepsy 1 (3%), migraine 3 (9%), chorea 1 (3%) and cognitive impairment 3 (9%). Renal in 4 (13%). Laboratory: prolonged aPTT 30 (93%), lupus anticoagulant 32 (100%), positive IgG anticardiolipin 20 (62%), positive IgM anticardiolipin 19 (60%). Anti-B2GPI was performed in only 3 patients, being positive in all. Treatment: anticoagulation in patients with thrombosis, antiplatelet in 23 (72%), steroid 30 (94%), immunosuppressant 30 (94%) and rituximab 4 (12.5%). No deaths were reported.

Conclusions: The clinical characteristics of patients with pediatric primary antiphospholipid syndrome differ from those presented in adults, since non-thrombotic manifestations are more frequent in children, for which classification criteria that include these manifestations are necessary for a better characterization of the disease in pediatric population.

Introduction

Antiphospholipid syndrome is an acquired immune mediated prothrombotic state. It is an important cause of thrombosis and obstetric loss. The history of this condition can be traced back to observations made during syphilis detection programs carried out in the first half...
of the twentieth century with the use of purified cardioli
pin mainly in the Venereal Disease Research Labora-
tory (VDRL) microfloculation assay. In 1952 researchers
from Johns Hopkins University reported an approximate
incidence of false positive VDRL in 20% of patients with
lupus, which was later associated with the presence of
lupus anticoagulant. In 1960, this in vitro anticoagulant
phenomenon was associated with thrombosis rather
than hemorrhage. Later in 1983, Harris used radioimmu-
noassay to show that at least two-thirds of serum sam-
ple from a group of 65 lupus patients had elevated levels
of anticardiolipin antibodies. In addition, 90% of these
patients who had lupus anticoagulant positivity had ele-
vated levels of anticardiolipin antibodies [1, 2].

It was in 1987 when the Hammersmith hospital group
proposed the first criteria for this syndrome, which
included three clinical criteria (arterial or venous throm-
busis, obstetric loss and thrombocytopenia) and two
laboratory criteria (LAC and ACL) [3, 4]. In subsequent
years, several authors began to describe other manifes-
tations associated with this syndrome such as chorea,
livedo reticularis, autoimmune hemolytic anemia, trans-
verse myelitis, migraine, epilepsy, Raynaud’s phenom-
emon, and cardiac valve lesions. In the late 1980s and
early 1990s, the term primary antiphospholipid syn-
drome was used when it was not associated with another
autoimmune disease. [3–10]. In 1992, other criteria were
described for the classification of the antiphospholipid
syndrome that complicates lupus, considering that to be
classified as an antiphospholipid syndrome, they should
meet two clinical criteria (livedo reticularis, recurrent
obstetric loss, venous thrombosis, thrombocytopenia,
hemolytic anemia, arterial thrombosis, skin ulcers) plus
elevated levels of antiphospholipid antibodies [11].

It was not until 1998 when the 8th International Sym-
posium on Antiphospholipid Antibodies was held in
Sapporo, Japan, addressed the need to unify criteria for
classification, define the essential characteristics of the
syndrome and facilitate treatment and etiology studies
and defined the clinical manifestations and laboratory
tests closely related to antiphospholipid syndrome. In
this consensus, vascular thrombosis and obstetric mor-
bidity remained as clinical criteria, and the presence of
LAC and ACL dependent on B2GPI as laboratory cri-
teria. Other clinical criteria (thrombocytopenia, auto-
immune hemolytic anemia, transverse myelitis, livedo
reticularis, heart valve disease, chorea and migraine)
were excluded as it was considered that there was no
strong evidence based on clinical or experimental inves-
tigations [12]. In 2004, the criteria were revised in Syd-
ney, adding anti-B2GPI antibodies to the laboratory
criteria [13]. These criteria was designed for non clini-
cal (research) purposes and are a useful tool to limit the
overdiagnosis of antiphospholipid syndrome; however,
they do not encompass all clinical manifestations, so
the final decision is always based on the judgment of the
treating physician [14].

At this point, it must be considered that these criteria
were based on studies carried out in adults and that in
children obstetric morbidity is rare, and the risk factors
for thrombosis are lower than those presented in adults,
so it is clear to assume that these manifestations are less
frequent in children, and that diagnostic criteria focused
on pediatric patients are needed. Therefore, the antiphos-
pholipid syndrome is not well defined in children and
there are no validated criteria for this age. The criteria
for adults are specific but lack sensitivity when applied
to children, so the incorporation of non-criteria clinical
manifestations is important in the pediatric population
[15].

Thus, prothrombotic risk factors such as age, smok-
ing, obesity, hypertension, dyslipidemia, diabetes, use of
oral contraceptives, pregnancy, congestive heart failure,
varicose veins and cancer are more frequent in adults
[16–18]. In contrast to these, prothrombotic risk factors
in children are trauma, surgery, neoplasm, nephrotic syn-
drome, congenital heart disease, obesity, central venous
catheters, prolonged immobilization, stay in the ICU,
burns and mechanical ventilation [19, 20], which are less
prevalent in this population, and might explain the lower
number of thrombotic events in pediatric antiphospho-
lipid syndrome.

Material and methods
A retrospective study was carried out in patients with
a diagnosis of primary antiphospholipid antibody syn-
drome, under 16 years of age, followed by the pediatric
rheumatology service of the General Hospital, National
Medical Center, La Raza, Mexico, from January 2013
to December 2020. Pediatric primary antiphospholipid
syndrome (PAPS) was defined when the child fulfilled
the laboratory criteria of the Sidney criteria on ≥2 occa-
sions at least 12 weeks apart and presented thrombosis
or non-criteria manifestations of the disease (hemato-
logical, neurological, cutaneous, renal, cardiac or pulmo-
nary). Demographic, clinical, laboratory, treatment, and
prognosis data were collected. Patients who did not meet
Sidney’s laboratory criteria, older than 16 years and who
had another associated rheumatological disease, were
excluded.

Descriptive statistics with frequencies and percent-
ages were used for categorical variables, in continuous
variables with mean, minimum and maximum. Associa-
tions between categorical variables were measured with
χ2, and for continuous variables with Mann-Whitney
U test or T test, using the SPSS 25 statistical software.
Results

We present the results of 32 patients, 21 female (65%) and 11 male (35%). The average age at diagnosis was 11.75 years (1–15 years): 12.2 years (1–15 years) in those with thrombosis, and 11.5 years (6 to 15 years) in those with only non-thrombotic manifestations. The average evolution time from the onset of symptoms was 16 weeks (1–108 weeks) in all patients: 7.5 weeks (1–28 weeks) in patients with thrombosis and 19 weeks (1–108 weeks) in patients without thrombosis. Thrombosis occurred in 9 patients (28%), 1 arterial and 8 venous, one site involving in 6 patients and 2 or more sites in 3. The most frequent site of venous thrombosis included the femoral vein and in the patient with arterial involvement it was cerebral.

Regarding non-thrombotic manifestations, hematological involvement was thrombocytopenia in 22 patients (69%), mean platelets with 119,000 (1,000–399,000) in all patients, but 54,000 (1,000–145,000) in patients with thrombocytopenia, autoimmune hemolytic anemia in 13 (40%), Fisher Evans syndrome in 6 (19%), leukopenia (<4500) in 4 (12.5%), lymphopenia (<1500) in 6, bleeding or ecchymosis in 16 (50%). The anemia was due to cold antibodies in 10, warm in 2 and mixed in 1. Lupus anticoagulant with hypoprothrombinemia syndrome was presented in 2 (6%). The dermatological manifestations were livedo reticularis in 20 (62%), skin ulcers in 2 (6%), and Raynaud’s phenomenon in 8 (25%). Neurological manifestations include: epilepsy 1 (3%), migraine 3 (9%), chorea 1 (3%) and cognitive impairment 3 (9.4%). No cardiopulmonary manifestations were observed. Renal involvement was found in 4 (13%) (nephrotic syndrome 1 and nephritic syndrome 3). (Table 1).

Exclusively non-thrombotic manifestations were observed in 23 patients (72%); only thrombotic in 1 (3%); thrombotic and non-thrombotic in 8 (25%). Among all patients with non-thrombotic manifestations, the combination of hematological (thrombocytopenia, autoimmune hemolytic anemia or lupus anticoagulant with hypoprothrombinemia syndrome) and cutaneous (livedo reticularis, Raynaud’s phenomenon, skin ulcers) was found in 16 (51%), hematological, cutaneous and renal (nephrotic or nephritic syndrome) in 2 (6%), hematological, cutaneous, renal and neurological (chorea, migraine, epilepsy) in 1 (3%), hematological, cutaneous and neurological in 3 (9%), hematological and neurological in 1 (3%), only hematological in 6 (19%), only renal in 1 (3%) and only cutaneous in 1 (3%). The majority of the patients (n = 22) presented hematological and cutaneous manifestations plus some other manifestation. The differences between the profile of clinical characteristics presented in patients with thrombosis and non-thrombotic manifestations are shown in Table 1.

In laboratory tests, prolonged aPTT was observed in 30 patients (93%), average of 77 s (27–124 s, normal value 30 s), a lupus anticoagulant in 32 (100%), average value 2 (1.22–3.39, normal value 1.2), anticardiolipin IgG antibodies in 20 (62%), mean value of 191 GPL (47–280 GPL), anticardiolipin IgM antibodies in 19 (60%), mean value of 153 MPL (41–255 MPL). AntiB2GPI was performed in only 3 patients, being positive in all. Regarding the presence of laboratory abnormalities supporting APS, two subjects had only the lupus anticoagulant, 10 subjects had both LAC and IgG anticardiolipin antibody, 8 had LAC with IgM ACL antibodies, and 9 had LAC with both IgM and IgG ACL antibodies. Of the three children with anti-II-B2GPI antibodies, 2 had LAC, ACL-IgM antibodies and anti-B2GPI IgG, and 1 had LAC, IgG ACL and anti-B2GPI IgG antibody. The differences between the laboratory profile presented in patients with thrombosis and non-thrombotic manifestations are shown in Table 2.

All patients of the 9 with thrombosis received anticoagulation (warfarin in 1, acenocoumarin in 3 and enoxaparin in 5). 23 (72%) received anti-platelet medication. 30 of 32 (94%) patients received glucocorticoid therapy, and 94% received immunosuppressant treatment (8 cyclophosphamide, 18 mycophenolate, and 4 azathioprine). Four (12.5%) received rituximab.

A difference was found between the aPTT value and the presence of thrombosis (97 vs 69 s p = 0.035). The anticardiolipin IgG value was lower in patients with autoimmune hemolytic anemia (68 vs 165, p = 0.022). IgM anticardiolipin values were significantly higher in patients with autoimmune hemolytic anemia (139 vs 66 p = 0.009). If the patient have a positive IgM ACL, a correlation was found with autoimmune hemolytic anemia (p = 0.016, RR 2.1, 95% CI 1.1–3.5). The antibody profile that was related to non-thrombotic manifestations was LAC+ACL IGM (p = 0.041 RR 1.53 95% CI 1.13–2.06). The presence of bleeding was higher in patients with a lower number of platelets (72,000 vs. 165,000 p = 0.007). There were no deaths in our patients.

Discussion

Epidemiology

There are no reliable data on the incidence and prevalence of pediatric PAPS, given the lack of validated criteria; however, of all cases of antiphospholipid syndrome in pediatric age, it is estimated that 24–50% are primary. The average age of presentation is from 10.7 to 14 years, but it can occur from the neonatal period to adolescence, with a male:female ratio of 1: 1.2. Up to 21% progress to SLE in 6 years [21–26]. The age of presentation coincides
with our results, the male: female ratio being a little higher at 1: 1.9 in our cohort.

**Clinical manifestations**

**Thrombosis**

In a study carried out by Avcin in 2008, in 121 pediatric patients with APS from 24 centers in 14 countries, it was found that 60 patients (49.5%) had PAPS, presenting with venous thrombosis in 60% (most frequently venous thrombosis of the lower extremities), arterial thrombosis in 32%, (more frequent ischemic (CVD) cerebrovascular disease), small vessel thrombosis (digital ischemia) in 6% and mixed in 2%. [27] Jingran reported a study of 58 patients with pediatric APS, finding venous thrombosis in 53% (deep vein thrombosis and pulmonary embolism) and arterial thrombosis in 21% [28]. Of these patients, 24% had PAPS. Amaluya reported 17 patients in a 20-year period at the Mayo Clinic in whom there was arterial thrombosis occurred in 35% and venous thrombosis in 65% [29]. In our study, venous thrombosis of the lower limbs was more frequent, which occurred in 89% of the patients who presented with thrombosis and only 1 patient with arterial thrombosis (11%).

An interesting study presented by Avcin at the 20th Pediatric Rheumatology European Society (PReS) Congress in 2013, followed 159 patients under 18 years of age with at least one positive antiphospholipid antibody for 6 years, of which only 25 (16%) presented thrombosis. (16 venous and 9 arterial), contrasting with other non-thrombotic manifestations such as hematological (30%), non-thrombotic neurological (16%) and cutaneous (3%), showing that thrombosis does not always develop in pediatric patients with positive antiphospholipid antibodies. [30] These results are different from our study.
since non-thrombotic manifestations were more frequent (97%) and thrombosis only occurred in 28%. In our 9 patients who presented with thrombosis, it was associated with hematological and skin manifestations in 7 (78%).

**Non-criteria manifestations**

**Hematological**

Thrombocytopenia is one of the main laboratory manifestations in pediatric PAPS, occurring in 8 to 38% of patients. It is usually moderate (> 50,000), bleeding is infrequent, and usually presents as petechiae or ecchymosis. The cause of thrombocytopenia is believed to be the direct binding of antiphospholipid antibodies to platelet phospholipids, antibodies to platelet glycoproteins, or platelet activation. Regarding autoimmune hemolytic anemia, it occurs in 6 to 21% of patients and has been associated with anticardiolipin positivity, heart valve disease and livedo reticularis and is due to a cross-reaction of antiphospholipids with phospholipids of the erythrocyte membrane (phosphatidylcholine). The combination of autoimmune hemolytic anemia with thrombocytopenia (Fisher Evans syndrome) occurs in 10% to 15% and is associated with very high levels of IgG and IgM anticardiolipins. Other manifestations that may occur but are very rare, are bone marrow necrosis and pure red series aplasia. [27, 28, 31, 32]. Another rare but life-threatening manifestation is the lupus anticoagulant with hypoprothrombinemia syndrome, which presents with prolonged PT and aPTT, positive lupus anticoagulant, and decreased factor II, due to anti-prothrombin antibodies that increase the clearance of factor II. The clinical manifestations in 74 patients with this complication were hemorrhage in 89% (51% severe, mainly gynecological) and thrombosis in 13% [33, 34]. The frequency of Fisher Evans syndrome coincides with that reported in the literature (19%). In our cohort of patients, 29 (90%) presented some hematological manifestation (thrombocytopenia, autoimmune hemolytic anemia or lupus anticoagulant syndrome with hypoprothrombinemia), being higher than that reported in the literature, but our study

| Table 2  Laboratory and treatment characteristics
| All patients $n=32$ (%) | Thrombosis $n=9$ (%) | Non-thrombotic $n=23$ (%) | $P$ value |
|-------------------------|---------------------|--------------------------|----------|
| Prolonged aPTT          | 30 (94%)            | 9 (100%)                 | 21 (91%) | 0.36      |
| Value in seconds (NV = 33 s) | 77 (27-124 s)     | 97 (41-124 s)           | 69 (27-120) | 0.033*   |
| Lupus anticoagulant (dRVVT) | 32 (100%)         | 9 (100%)                 | 23 (100%) |          |
| Value (NV < 1.2)        | 2.07                | 2.13                     | 2.05     | 0.71      |
| Anticardiolipin antibodies | 8 (88%)            | 8 (88%)                  | 21 (91%) |          |
| IgG                     | 20 (63%)            | 6 (66%)                  | 14 (61%) | 0.76      |
| Value (NV < 40)         | 191 GPL             | 188 GPL                  | 192 GPL  | 0.86      |
| IgM                     | 19 (59%)            | 4 (44%)                  | 15 (65%) | 0.28      |
| Value (NV < 40)         | 153 MPL             | 154 MPL                  | 153 MPL  | 0.50      |
| Antibody profile        |                     |                          |          |          |
| LAC                     | 2 (6%)              | 1 (11%)                  | 1 (4%)   | 0.47      |
| LAC + ACL IgG           | 10 (31%)            | 4 (44%)                  | 6 (26%)  | 0.31      |
| LAC + ACL IgM           | 8 (25%)             | 0                        | 8 (35%)  | 0.041*    |
| LAC + ACL IgG + IgM     | 9 (28%)             | 2 (22%)                  | 7 (30%)  | 0.64      |
| LAC + ACL IgM + B2GPI   | 2 (6%)              | 2 (22%)                  | 0        |          |
| LAC + ACL IgG + B2GPI   | 1 (3%)              | 0                        | 1 (4%)   |          |
| Treatment               |                     |                          |          |          |
| Anticoagulation         | 9 (28%)             | 9 (100%)                 | 0        |          |
| Antiplatelet            | 23 (72%)            | 0                        | 23 (100%)|          |
| Steroid                 | 30 (94%)            | 8 (88%)                  | 22 (96%) |          |
| Immunosuppressant       | 30 (94%)            | 8 (88%)                  | 22 (96%) |          |
| Cyclophosphamide        | 8 (25%)             | 6 (66%)                  | 2 (9%)   |          |
| Mycophenolate           | 18 (56%)            | 1 (11%)                  | 17 (74%) |          |
| Azathioprine            | 4 (13%)             | 1 (11%)                  | 3 (13%)  |          |
| Rituximab               | 4 (13%)             | 2 (22%)                  | 2 (9%)   |          |

*aPTT Activated partial thromboplastin time, LAC Lupus anticoagulant, ACL Anticardiolipin antibodies, NV Normal value, dRVVT Diluted Russell Viper Venom Time*
included patients with non-thrombotic manifestations, which likely explains the difference.

**Dermatological manifestations**
Skin manifestations occur in 18 to 26% of pediatric PAPS patients and though none are pathognomonic, livedo reticularis and Raynaud’s phenomenon being the most frequent and digital gangrene and skin ulcers less frequent [27, 28, 35]. In our patients, 71% presented with skin manifestations (livedo reticularis, Raynaud’s phenomenon or skin ulcers), being greater than that reported in the literature.

**Neurological manifestations**
Neurological manifestations in antiphospholipid syndrome can be related to thrombosis, inflammation, and direct effects of APL antibodies on neuronal function. Non-thrombotic neurologic manifestations occur in 12–16% of patients and include migraine headache, chorea, epilepsy, pseudotumor cerebri, and conduct disorders [27, 36]. Headache is the most common symptom (20%), but large studies have failed to establish a relationship with APS. Nevertheless, some patients respond to anticoagulation management. Seizures occur in 3–8% and the pathogenesis may be related to microthrombosis or immune-mediated neuronal damage. Seizures are associated with the presence of thrombocytopenia and livedo reticularis. Chorea is rare and occurs in 1.3 to 4.5%. Chorea can be generalized or unilateral and is due to the effect of antiphospholipid antibodies on the basal ganglia. Other manifestations that can be observed are multiple sclerosis like, transverse myelitis, psychosis, and Guillian Barre-like syndrome [36–39] In our study, we found neurological manifestations in 16% (chorea, epilepsy, migraine and cognitive defects), which is consistent with the literature. It is important to mention that in our study, at least two neurological manifestations were found in each patient with neurologic involvement.

**Cardiopulmonary manifestations**
Heart valve abnormalities are seen in 40 to 60% of adults but are rarely seen in pediatric patients; other manifestations are coronary occlusive disease, cardiomyopathy, and intracardiac thrombosis [40, 41]. Pulmonary manifestations mainly comprise pulmonary thrombembolism, and rarely pulmonary hypertension, alveolar hemorrhage, fibrosing alveolitis and pulmonary infarction [42, 43]. In our study, thrombotic or non-thrombotic cardiac or pulmonary manifestations were not observed, which contrasts with the data obtained in the adult population.

**Renal manifestations**
Thrombotic renal manifestations occur in 1 to 3%, include thrombotic microangiopathy, renal vein thrombosis, and renal artery thrombosis or stenosis, however, not only renovascular involvement is observed, since minimal change disease, membranous, proliferative glomerulonephritis and mesangial nephropathy may also occur [27, 44–46]. We did not observe cases of thrombotic microangiopathy, only 3 patients with nephritic syndrome and one with nephrotic syndrome, the latter associated with renal vein thrombosis. Kidney biopsy was not performed in any patient.

**Laboratory**
In the adult APS classification criteria, persistent lupus anticoagulant, anticardiolipin and anti-B2GPI antibodies are considered, requiring they be positive for at least 12 weeks. It is recommended to perform the three tests (LAC, ACL and anti B2GPI) to stratify the risk of thrombosis. In patients with pediatric PAPS, the presence of anticardiolipin was found in 82% (IgG 37%, IgM 22%, both 28%), anti B2GPI in 70% (IgG 35%, IgM 17%, both 17%) and lupus anticoagulant in 72% [27, 47]. In our study, lupus anticoagulant was found in 100%, positive anticardiolipin in 91% (IgG 33%, IgM 31%, both 27%) being similar than previously reported. Only 2 patients had abnormal results in a single test (LAC), and the rest of the patients had 2 or 3 positive tests. Unfortunately, in our institution, the determination of antiB2GPI is not routinely utilized, so it was only performed in 3 patients, in all of whom, it was positive. No antibody profile was associated with the presence of thrombosis in our study.

**Treatment**
In 2017, the SHARE initiative issued recommendations for the treatment of pediatric APS, focusing on the thrombotic manifestation. These include the use of antimalarials, antiplatelet agents and anticoagulants [15].

For non-thrombotic manifestations, multiple treatments have been used depending on the type of manifestation, such as glucocorticoids and immunosuppressants (IVIG, azathioprine, mycophenolate, cyclosporine, cyclophosphamide, plasmapheresis and rituximab), as well as symptomatic treatments when necessary (anti-epileptics, antihypertensives, vasodilators). In our study, since most of the patients presented 2 to 3 clinical manifestations, the use of steroids and immunosuppressants occurred in 30 patients (94%). Rituximab was used in 4 patients.
(2 with thrombocytopenia, 1 with thrombocytopenia, thrombosis, neurological and kidney disease, and 1 with thrombosis and kidney disease).

Classification criteria
There are no validated criteria for the diagnosis of pediatric PAPS. The Sydney criteria were adapted for the pediatric population and excluded obstetric morbidity, however these criteria are only used for research purposes to homogenize populations [48]. For clinical and diagnostic purposes, they are not useful, since as we demonstrated previously, the clinical manifestations of pediatric patients with persistently positive antiphospholipid antibodies go beyond thrombosis. In fact, non-thrombotic manifestations are even more frequent than thromboses in children. Therefore we suggest incorporating these non-thrombotic APS manifestations (hematological, cutaneous, neurological and renal) to the criteria in order to allow earlier diagnosis, prevent damage, and improve their quality of life with adequate treatment.

Efforts have been made to include new manifestations in the criteria for the classification of antiphospholipid syndrome, including cardiac, hematological, macrovascular, microvascular and neurological manifestations, however, clinical studies are still needed to validate them and their focus is not on pediatric patients. [49, 50].

Conclusions
Antiphospholipid syndrome in the pediatric age group cannot continue to be studied as in adult patients, since the characteristics of this population are different, considering that thrombotic and obstetric manifestations are less frequent at this age, given the absence of obstetric morbidity and the lower frequency of prothrombotic risk factors, making non-thrombotic manifestations of the disease more evident, such as those mentioned in this study. There is a need to redefine this syndrome in the pediatric population as mentioned above and to generate its own classification criteria, in order to improve epidemiological, clinical and treatment studies of this type of patients.

Abbreviations
aPTT: Activated partial thromboplastin time; VDRL: Venereal disease research laboratory microflocculation assay; LAC: Lupus anticoagulant; ACL: Anticardiolipin antibodies; ICU: Intensive care unit; SLE: Systemic lupus erythematosus; PAPS: Primary antiphospholipid syndrome; CVD: Cerebrovascular disease; APS: Antiphospholipid syndrome; SHARE: Single Hub and Access point for paediatric Rheumatology in Europe; IVIG: Intravenous immunoglobulin; LAHP: Lupus anticoagulant with hypoprothrombinemia syndrome; AIHA: Autoimmune hemolytic anemia.

Authors’ contributions
All authors contributing to the conduction of the study, read and approved the final manuscript.
45. Sciascia S, Cuadrado MJ, Khamashta M, Roccatello D. Renal involvement in antiphospholipid syndrome. Nat Rev Nephrol. 2014;10(5):279–89. https://doi.org/10.1038/nrneph.2014.38 Epub 2014 Mar 18 PMID: 24642799.

46. Tektonidou MG. Antiphospholipid Syndrome Nephropathy: From Pathogenesis to Treatment. Front Immunol. 2018;9(0):1181. https://doi.org/10.3389/fimmu.2018.01181 PMID:29904380 PMCID:PMC5990608.

47. Tebo AE. Laboratory Evaluation of Antiphospholipid Syndrome: An Update on Autoantibody Testing. Clin Lab Med. 2019;39(4):553–65. https://doi.org/10.1016/j.cll.2019.07.004 Epub 2019 Oct 4 PMID: 31668269.

48. Aguiar CL, Soybilgic A, Avicin T, Myones BL. Pediatric antiphospholipid syndrome. Curr Rheumatol Rep. 2015;17(4):27. https://doi.org/10.1007/s11926-015-0594-5 PMID: 25854492.

49. Abreu MM, Danowski A, Wahl DG, Amigo MC, Tektonidou M, Pacheco MS, Fleming N, Domingues V, Sciascia S, Lyra JO, Petri M, Khamashta M, Levy RA. The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev. 2015;14(5):401–14. https://doi.org/10.1016/j.autrev.2015.01.002 Epub 2015 Jan 29 PMID: 25641203.

50. Barbhaiya M, Zully S, Ahmadvazdeh Y, Amigo MC, Avicin T, Bertolaccini ML, Branch DW, de Jesus G, Devreese KMJ, Frances C, Garcia D, Guillemin F, Levine SR, Levy RA, Lockshin MD, Ortell TL, Seshan SV, Tektonidou M, Wahl D, Willis R, Naden R, Costenbader K, Erkan D, New APS Classification Criteria Collaborators. Development of a new international antiphospholipid syndrome classification criteria phase i/ii report: generation and reduction of candidate criteria. Arthritis Care Res (Hoboken). 2021;73(10):1490–501. https://doi.org/10.1002/acr.24520 Epub 2021 Sep 2 PMID: 33253499.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.